Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Dashboard
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Articles
More+
Staffing
Media Kit
Membership Levels
By The Numbers
Drug Development
372 Articles Available
1
16
Can't find what you're looking for? Try our
advanced search
.
Research
Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease
PR-M03-19-NI-067
Collaboration
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
PR-M03-19-NI-057
FDA Approval
Allergan Announces FDA Approval of AVYCAZ® (ceftazidime and avibactam) for Pediatric Patients
PR-M03-19-NI-054
Preclinical Data
Alligator Bioscience: New Preclinical Data Demonstrate Strong Anti-tumor Effects for the 4-1BB Antibody ATOR-1017
PR-M03-19-NI-053
Real-World Analysis
XARELTO® Significantly Reduced Ischemic Stroke in Real-World Meta-Analysis of Non-Vitamin K Antagonist Oral Anticoagulants
PR-M03-19-NI-044
Microbiome
The Global Human Microbiome Market is Expected to Reach US$ 1,197.08 Mn in 2025 from US$ 257.30 Mn in 2017
PR-M03-19-NI-041
Enpoint
Lilly's CYRAMZA® Phase 3 RELAY Trial Met Primary Endpoint in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
PR-M03-19-NI-039
Clinical Results
Lipocine's LPCN 1144 for NASH Demonstrates Substantial Fatty Liver Resolution and Meaningful Liver Fat Reduction in NAFLD Population
PR-M03-19-NI-038
Assay
ForteBio Introduces New Product for High-Throughput Glycan Screening
PR-M03-19-NI-036
Priority Review
FDA Grants Priority Review to Dupixent for Treatment of Adults with Severe Chronic Rhinosinusitis
PAO-M03-19-NI-017
Virtual Panel
Reprioritizing to Bring FY2020 into Focus
PAP-Q1-2019-CL-032
Artificial Intelligence
Pharma Makes Moves to Leverage Artificial Intelligence
PAP-Q1-2019-NI-006
Biosimilars
Accelerating Biosimilar Development
PAP-Q1-2019-CL-014
Immunotherapy
Collaborating for Immunotherapy Development
PAP-Q1-2019-NI-007
HIV
Long-Acting Injectable HIV Treatment Regimen of Rilpivirine and Cabotegravir Demonstrated Comparable Safety and Efficacy to Daily Oral HIV Therapy
PR-M03-19-NI-033
Oncology
Real World Evidence on Use of Halaven® (eribulin mesylate) Injection Following CDK 4/6 Inhibitor to be Presented at 36th Annual Miami Breast Cancer Conference
PR-M03-19-NI-029
FDA Approval
FDA Approves New Nasal Spray Medication for Treatment-resistant Depression; Available Only at a Certified Doctor's Office or Clinic
PR-M03-19-NI-027
Clinical Trials
Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study
PR-M03-19-NI-016
Drug Pricing
Diabetes Patients Look Forward to Lower-Priced Insulin
PAO-M03-19-NI-015
Drug Pricing
How Do You Classify Fecal Microbiota?
PAO-M03-19-NI-012
Innovation
Innovative Tech Might Make Infrared Vision Possible
PAO-M03-19-NI-010
Drug Development
Novartis Licenses First-in-Class Heart Disease Drug
PAO-M03-19-NI-008
Collaboration
New Collaboration Targets Parkinson’s Disease
PAO-M03-19-NI-005
Clinical Study
Inovio Initiates REVEAL 2 Global Phase 3 Clinical Study For the Treatment of HPV-Related Cervical Pre-cancer
PR-M03-19-NI-012
1
16
»
